Financial Performance - The company's operating revenue for Q1 2025 was CNY 995,933,663.32, representing a decrease of 8.56% compared to CNY 1,089,195,256.05 in the same period last year[4] - Net profit attributable to shareholders was CNY 269,880,235.57, down 16.76% from CNY 324,212,004.34 year-on-year[4] - Basic and diluted earnings per share were both CNY 0.47, reflecting a decrease of 16.07% compared to CNY 0.56 in the previous year[5] - The weighted average return on equity decreased by 0.65 percentage points to 3.09% from 3.74%[5] - Total operating revenue for Q1 2025 was ¥995,933,663.32, a decrease of 8.6% compared to ¥1,089,195,256.05 in Q1 2024[19] - Net profit for Q1 2025 was ¥273,079,722.47, a decline of 17.0% from ¥328,699,468.29 in Q1 2024[20] - The company reported a total comprehensive income of ¥273,067,610.47 for Q1 2025, down from ¥328,712,789.76 in Q1 2024[21] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 49.35%, amounting to CNY 166,338,458.26, primarily due to a significant decline in sales receipts[8] - Cash received from sales of goods and services in Q1 2025 was ¥1,121,264,719.60, a decrease of 10.6% from ¥1,254,041,270.41 in Q1 2024[24] - The net cash flow from operating activities was $166,338,458.26, a decrease of 49.3% compared to $328,402,122.27 in the previous period[25] - The ending balance of cash and cash equivalents was $219,525,703.08, down from $1,077,430,057.76 year-over-year[27] - The company's cash and cash equivalents decreased to RMB 232,830,899.63 from RMB 465,373,123.02[14] Assets and Liabilities - Total assets at the end of the reporting period were CNY 11,968,031,676.54, an increase of 0.78% from CNY 11,875,065,943.97 at the end of the previous year[5] - Total liabilities decreased to ¥2,998,174,827.59 in Q1 2025 from ¥3,183,270,091.04 in Q1 2024, a reduction of 5.8%[17] - Accounts receivable stood at RMB 1,096,610,904.01, slightly down from RMB 1,138,995,430.17[15] - Inventory increased to RMB 1,170,654,495.92 from RMB 1,153,089,499.27[15] Shareholder Information - Shareholders' equity attributable to the parent company increased by 3.02% to CNY 8,876,936,827.16 from CNY 8,616,530,318.04[5] - The total number of ordinary shareholders at the end of the reporting period was 34,163[10] - The largest shareholder, Zhengzhou Antu Industrial Group Co., Ltd., holds 57.65% of the shares, totaling 329,445,773 shares[10] - The company has no related party relationships among the top ten shareholders, ensuring independent ownership structures[12] Future Outlook and Strategy - The company is focusing on expanding its market presence and enhancing product development strategies[12] - Future guidance and performance outlook will be provided in subsequent earnings calls[12] Expenses - Total operating costs for Q1 2025 were ¥746,443,403.96, down 4.0% from ¥777,943,233.44 in Q1 2024[19] - Research and development expenses for Q1 2025 were ¥130,563,085.75, down 13.7% from ¥151,149,747.29 in Q1 2024[20] - Cash outflow for purchasing goods and services was $373,420,356.81, up from $342,713,332.33 in the previous period[25] - Cash paid to employees increased to $476,776,379.07 from $434,312,784.10 year-over-year[25] - Cash paid for taxes decreased to $72,647,267.29 from $109,465,529.66 in the previous period[25] - Cash paid for other operating activities was $121,760,849.59, slightly up from $117,221,314.12 year-over-year[25]

Financial Performance - The company's operating revenue for 2024 reached ¥4,471,202,509.22, a slight increase of 0.62% compared to ¥4,443,655,727.69 in 2023[25]. - The net profit attributable to shareholders for 2024 was ¥1,194,451,909.72, reflecting a decrease of 1.89% from ¥1,217,438,887.27 in 2023[25]. - The net cash flow from operating activities decreased by 10.92% to ¥1,309,282,741.12 in 2024, down from ¥1,469,855,864.22 in 2023[25]. - The total assets of the company increased by 2.78% to ¥11,875,065,943.97 in 2024, compared to ¥11,554,058,269.37 in 2023[25]. - The basic earnings per share for 2024 was ¥2.07, a decrease of 1.43% from ¥2.10 in 2023[26]. - The weighted average return on equity decreased to 13.92% in 2024 from 14.92% in 2023, a reduction of 1 percentage point[26]. - The net profit after deducting non-recurring gains and losses for 2024 was ¥1,098,820,497.48, down 7.30% from ¥1,185,306,158.13 in 2023[25]. - The company reported a decrease in operating costs to CNY 1,546,573,971.03, down 0.84% from the previous year[105]. - The company’s R&D expenses increased by 11.55% to CNY 731,932,785.27, indicating a commitment to innovation and product development[105]. Dividend and Share Repurchase - The company plans to distribute a cash dividend of RMB 1.26 per share, totaling RMB 719,995,207.68, which represents 60.28% of the net profit attributable to shareholders for the reporting period[6]. - The total amount for cash dividends and share repurchases is RMB 1,156,354,571.73, accounting for 96.81% of the net profit attributable to shareholders for the year[6]. - The company has implemented a share repurchase program totaling RMB 436,359,364.05, which includes transaction costs[6]. Research and Development - The company achieved R&D investment of CNY 73.19 million, accounting for 16.37% of total revenue[36]. - The company has established a comprehensive technical R&D system with multiple centers, enhancing its capability in cutting-edge technology and product development[72]. - The company is focusing on enhancing its immunodiagnostic product line, with multiple new antibody calibrators and test kits set for approval in June 2024[131]. - The company is actively pursuing regulatory approvals for new products, which is crucial for maintaining competitive advantage in the healthcare market[60][81]. Product Development and Innovation - The company successfully developed 144 new reagent products, enhancing its product series and brand influence[37]. - The AutoChem B2000 and AutoChem B800 series fully automated biochemical analyzers were launched, providing flexible solutions for large medical laboratories[38]. - The company launched three gene sequencers (Sikun 2000, Sikun 1000, Sikun 500) and an automated pathogen analysis system (APAS) in 2024[40]. - The company has developed a fully automated microbial mass spectrometry detection system, Autof ms series, which is widely used in clinical and public health applications[82]. - The company is expanding its product line with a focus on biochemical detection and immunodiagnostics, indicating a strategic move to capture a larger market share in these segments[57][60][79]. Market Trends and Industry Insights - The global in vitro diagnostic (IVD) market is projected to reach $109.2 billion in 2024, with a stable growth forecast to $140 billion by 2027[45]. - The Chinese IVD market reached ¥118.5 billion in 2023, with expectations to exceed ¥120 billion in 2024, driven by increasing health awareness and early diagnosis needs[50]. - The immunodiagnostics segment is the largest in China, with a market size of ¥50.3 billion in 2023, growing 13% year-on-year, accounting for 42.45% of the market share[51]. - The molecular diagnostics market in China reached ¥14.8 billion in 2023, representing 12.49% of the market, and is one of the fastest-growing segments due to its high sensitivity and specificity[51]. Governance and Compliance - The board of directors and management confirm the authenticity, accuracy, and completeness of the annual report[3]. - The company has not violated decision-making procedures for external guarantees[8]. - The company emphasizes that forward-looking statements regarding future plans and strategies do not constitute a commitment to investors, highlighting investment risks[7]. - The company has established a robust governance structure, ensuring compliance with relevant laws and regulations to maximize shareholder interests[166]. Financial Management and Capital Structure - The company reported a foreign exchange swap investment with a fair value change gain of RMB 3.61 million during the reporting period[147]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to CNY 990.44 million[184]. - The company is actively managing its capital structure, including proposals to adjust registered capital and amend its articles of association[188]. Employee and Workforce Management - The total number of employees in the company is 5,773, with 2,580 in major subsidiaries[199]. - The company has established a comprehensive compensation and benefits system, combining fixed and variable pay based on performance[200]. - The educational background of employees includes 295 with below college education, 1,403 with college diplomas, 2,914 with bachelor's degrees, and 1,161 with master's degrees or higher[199]. Strategic Partnerships and Market Expansion - The company is exploring potential acquisitions to enhance its market position, with a budget of $100 million allocated for this purpose[177]. - The company plans to enter two new international markets by Q2 2024, aiming for a 10% contribution to overall revenue[177]. - The company is focused on expanding its market presence through strategic partnerships and board appointments in various related companies[175].

2024 年度利润分配预案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例：A 股每股派发现金红利 1.26 元（含税）。 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体 日期将在权益分派实施公告中明确。在实施权益分派的股权登记日前公司总股 本发生变动的，拟维持分配总额不变，相应调整每股派发现金红利。 证券代码：603658 证券简称：安图生物 公告编号：2025-022 郑州安图生物工程股份有限公司 本次利润分配不送股、不进行资本公积转增股本。如在本公告披露之日起至 实施权益分派股权登记日期间，因可转债转股/回购股份/股权激励授予股份回购 注销/重大资产重组股份回购注销等致使公司总股本发生变动的，公司拟维持分 配总额不变，相应调整每股分配金额。如后续总股本发生变化，将另行公告具体 调整情况。 本次利润分配预案尚需提交公司 2024 年年度股东大会审议。 项目 2024年度 2023年度 2022年度 现金分红总额（元） 719,995,207.68 608,800,164.62 ...

安图生物（603658）公告，2025年第一季度营收为9.96亿元，同比下降8.56%；净利润为2.7亿元，同比 下降16.76%。 ...

证券代码：603658 证券简称：安图生物 公告编号：2025-019 郑州安图生物工程股份有限公司 关于使用闲置募集资金进行现金管理 赎回及进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1 现金管理种类：大额存单 现金管理金额：5,000 万元非公开发行股票闲置募集资金； 履行的审议程序：郑州安图生物工程股份有限公司（以下简称"公司"）于 2024 年 12 月 11 日召开第五届董事会第二次会议、第五届监事会第二次会 议，审议通过《关于使用部分闲置募集资金进行现金管理的议案》，同意 公司在确保不影响募集资金投资项目建设和募集资金使用的情况下，公司 拟分别使用不超过 1.7 亿元公开发行可转换公司债券闲置募集资金和不超 过 17 亿元非公开发行股票闲置募集资金进行现金管理，分别用于购买单次 持有期限不超过 12 个月的结构性存款、大额存单、国债逆回购、券商收益 凭证、券商理财产品等安全性高、流动性好的保本型产品。在上述额度范 围内，资金可在 12 个月内滚动使用。具体内容详见公司于 2024 年 ...

截至2025年4月3日收盘，安图生物(603658)报收于42.75元，上涨0.19%，换手率0.43%，成交量2.44万 手，成交额1.04亿元。 董秘最新回复 投资者： 许多科技巨头开始进军AI医疗领域，安图作为体外诊断全品类的头部企业，我们一定要积极 把握AI技术对传统IVD行业的变革，从而让安图生物从传统IVD企业向AI体外诊断医疗科技企业的转 型，加强与知名医疗机构的合作共享，建立起属于安图的诊断数据库以及AI诊断模型，为安图生物的 AI诊断领域的发展奠定坚实的基础，希望董秘能把普通股东的想法意见转达给管理层！谢谢…… 董秘： 尊敬的投资者您好，感谢您对公司的关注与建议。公司多年来一直积极探索人工智能技术、检 验设备与检验业务的深度融合，并利用AI技术不断赋能检验设备。未来，公司将继续深化AI技术在检 验医学中的应用，不断探索和拓展AI技术在疾病预防、诊断、治疗和管理等各个环节的潜力，推动检 验医学的智慧化发展。谢谢。 投资者： 通过尿液检测H-FABP的半定量试纸，可实现居家自检，日常心血管健康监测，早期辅助诊断 心肌梗死，评估心肌早期微损伤，检测心肌炎/监测心力衰竭预后，对挽救患者的生命起到重要 ...

一、医疗器械注册证的具体情况 证券代码：603658 证券简称：安图生物 公告编号：2025-018 郑州安图生物工程股份有限公司 关于获得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 郑州安图生物工程股份有限公司（以下简称"公司"或"安图生物"）于近 日收到国家药品监督管理局、河南省药品监督管理局颁发的医疗器械注册证，具 体如下： | 编号 | 产品名称 | 注册证编号 | 注册证 有效期 | 预期用途 | | --- | --- | --- | --- | --- | | 1 | 肺炎支原体抗原检测 | 国械注准 | 5 年 | 本产品用于体外定性检测人口咽拭子中 | | | 试剂盒（胶体金法） | 20253400589 | | 的肺炎支原体（MP）抗原。 本产品用于定性检测女性阴道分泌物中 | | 2 | 阴道炎联合检测试剂 盒（干化学酶法） | 豫械注准 20252400184 | 5 年 | 的过氧化氢、白细胞酯酶、凝固酶、脯 氨酸氨基肽酶、唾液酸苷酶、乙酰氨基 葡萄糖苷酶、葡萄糖苷酶、pH ...

安图生物: 安图生物关于全资子公司完成工商变更 登记的公告 证券代码：603658 证券简称：安图生物 公告编号：2025-017 郑州安图生物工程股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 郑州安图生物工程股份有限公司（以下简称"公司"或"安图生物"）于近 日收到全资子公司安图实验仪器（郑州）有限公司（以下简称"安图仪器"）通 知，安图仪器对法定代表人进行了变更，目前已完成工商变更登记，并取得了郑 州经济技术开发区市场监督管理局换发的新《营业执照》，主要信息如下： 类医疗器械生产；道路货物运输（不含危险货物）；国际道路货物运输；医疗器 械互联网信息服务。（依法须经批准的项目，经相关部门批准后方可开展经营活 动，具体经营项目以相关部门批准文件或许可证件为准） 一般项目：第二类医疗器械销售；第一类医疗器械生产；第一类医疗器械销 售；工程和技术研究和试验发展；实验分析仪器制造；实验分析仪器销售；计算 机软硬件及辅助设备零售；软件开发；软件销售；信息系统集成服务；信息系统 运行维护服务；货物进出口；技术进出口；技术 ...

证券代码：603658 证券简称：安图生物 公告编号：2025-017 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 郑州安图生物工程股份有限公司（以下简称"公司"或"安图生物"）于近 日收到全资子公司安图实验仪器（郑州）有限公司（以下简称"安图仪器"）通 知，安图仪器对法定代表人进行了变更，目前已完成工商变更登记，并取得了郑 州经济技术开发区市场监督管理局换发的新《营业执照》，主要信息如下： 1. 统一社会信用代码：914101007991755210 6. 注册资本：伍仟万圆整 7. 成立日期：2007年03月15日 8. 经营范围：许可项目：第三类医疗器械生产；第三类医疗器械经营；第二 类医疗器械生产；道路货物运输（不含危险货物）；国际道路货物运输；医疗器 械互联网信息服务。（依法须经批准的项目，经相关部门批准后方可开展经营活 动，具体经营项目以相关部门批准文件或许可证件为准） 一般项目：第二类医疗器械销售；第一类医疗器械生产；第一类医疗器械销 售；工程和技术研究和试验发展；实验分析仪器制造；实验分析仪器销售；计算 机 ...

证券代码：603658 证券简称：安图生物 公告编号：2025-016 郑州安图生物工程股份有限公司 关于获得医疗器械注册证的公告 上述医疗器械注册证的取得进一步丰富了公司产品菜单，不断满足市场需 求，是对公司现有检测产品的有效补充，可以逐步提高公司产品的整体竞争力， 短期内对公司的经营业绩影响较小。 四、风险提示 上述产品上市后实际销售情况取决于未来市场的推广效果，目前尚无法预测 上述产品对公司未来营业收入的影响，敬请投资者注意投资风险。 特此公告。 | 编号 | 产品名称 | 注册证编号 | 注册证 有效期 | 预期用途 | | --- | --- | --- | --- | --- | | 1 | 鲍曼不动杆菌/嗜麦芽窄 食单胞菌/洋葱伯克霍尔 | 国械注准 | 5 年 | 用于体外定性检测痰液样本中的鲍 曼不动杆菌/嗜麦芽窄食单胞菌/洋葱 | | | 德 菌 核 酸 检 测 试 剂 盒 （PCR-荧光探针法） | 20253400474 | | 伯克霍尔德菌核酸。 | | 2 | 丙型肝炎病毒核酸检测 | 国械注准 | | 本试剂盒用于体外定量检测人血清 或血浆中的丙型肝炎病毒（HCV） | | | ...